Navigation Links
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
Date:11/12/2007

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, November 14, 2007 at 8:30 A.M. EST to discuss the First Quarter fiscal 2008 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1-800-926-9907 (North America), 1-212-231-2913 (International).

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...mab) drug is found to be useful in treating patien... by the European Medicines Agency (EMEA) for use i...rrent drugs//. Xolair can be used in the treatment...effects of the new drug on long time usage has to ...
... suggests that the melanocortin system is an impor...al neuronal plasticity observed after chronic morp... is accompanied by the development of morphine tol...ms associated with opiate treatment. Possible modu...
...m Italy have designed a closed circuit, where Umbi...n are performed, in order to reduce the contaminat...n//. Their findings appear in the journal Blood C...le online 19 August 2005)Umbilical cord blood is a...
...cal tourism is currently the buzz word of Indian h...g from USA and Canada for niche high cost orthoped...e replacement. // The fact that surgeries by many... and they have wide experience helps to win over t...
Other Medicine News:Health News:Inhibition of morphine tolerance by spinal melanocortin receptor blockade 2Health News:A Novel System For Clinical Banking Of Umbilical Cord Blood 2Health News:India - Favored Orthopedics Surgery Destination 2Health News:India - Favored Orthopedics Surgery Destination 3
(Date:9/5/2008)...lif., Sept. 5 /- SARcode,Co...cule LFA-1 inhibitors,to treat inflammatory diseas...S) today announced SARcode,s initiation of a Phase...t candidate for T-cell mediated ophthalmic,disease...ement providing,SARcode with an exclusive license ...
(Date:9/4/2008)...ept. 4 /- Cytopia Limited (ASX:,CYT) ...r its Phase Ib/II,study of CYT997, the company,s n...ents with an aggressive form of brain cancer known...cal trial is the first Phase II efficacy study in ...ompany and the second in its,suite of Phase II stu...
(Date:9/4/2008)...Man(R) real-time PCR testing for the diagnostic ...alif., Sept. 4 /- The U.S. Food & Dru...S(R) TaqMan(R) HBV Test,the first assay for quant...,The test uses Roche,s real-time PCR technology to... patient,s blood. Doctors may use viral load,testi...
(Date:9/4/2008)... 4 /- Southern Research Institute,tod...h (NIH) has selected,the organization to participa...roduction Center Network (MLPCN). The MLPCN -- a c...lecular Libraries Program which is,designed to ben... the human,genome and validate future targets for ...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Coalition of Caregivers Warns Congress of Danger to Oldest U S Seniors if Medicare Slashed 5228 1Coalition of Caregivers Warns Congress of Danger to Oldest U S Seniors if Medicare Slashed 5228 2Coalition of Caregivers Warns Congress of Danger to Oldest U S Seniors if Medicare Slashed 5228 3Coalition of Caregivers Warns Congress of Danger to Oldest U S Seniors if Medicare Slashed 5228 4New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus 28MRSA 29 1653 1New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus 28MRSA 29 1653 2Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 1649 1Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 1649 2Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 1649 3Mayo Clinic Study Shows Drug Could Effectively Treat Prevent the Spread of Breast Cancer 720 1Mayo Clinic Study Shows Drug Could Effectively Treat Prevent the Spread of Breast Cancer 720 2Mayo Clinic Study Shows Drug Could Effectively Treat Prevent the Spread of Breast Cancer 720 3
...Abbott,s Bioabsorbable Stent Technology Holds Prom...icians Treating Patients,with Coronary Artery Dise...-FirstCall/ --,Abbott today announced positive res... evaluating the overall safety and performance,of ... for the,treatment of coronary artery disease. Six...
...Initial Analysis Shows Statistically Significant C... ALTO, Calif., March 26, 2007 /PRNewswire-FirstCal... positive initial,results from its Phase IIa clini...zophrenic patients with acute agitation. The 10 mg...inical trial,which was a statistically-significan...
Other Medicine Technology:Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 2Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6
...nd medium volume laboratories, as well as specialt...simplicity and flexibility needed to respond to mu... the Elecsys 1010 system enables operators to hand...e testing without sacrificing ease of operation or...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
...stry System provides high-performance detection te...c proteins and therapeutic drugs. It also delivers...ow the laboratory to streamline its operations and...esign enables numerous functions to be performed s...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca
Medicine Products: